↓ Skip to main content

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, December 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
2 news outlets
twitter
8 tweeters
facebook
3 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
64 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Published in
Arthritis Research & Therapy, December 2016
DOI 10.1186/s13075-016-1190-z
Pubmed ID
Authors

Jérémie Sellam, Elodie Rivière, Alice Courties, Paul-Olivier Rouzaire, Barbara Tolusso, Edward M. Vital, Paul Emery, Gianfranco Ferraccioli, Martin Soubrier, Bineta Ly, Houria Hendel Chavez, Yassine Taoufik, Maxime Dougados, Xavier Mariette

Abstract

Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We aimed to study the possible association between serum IL-33 detection and response to rituximab (RTX) in rheumatoid arthritis (RA) patients in different cohorts with an accurate enzyme-linked immunosorbent assay (ELISA). Serum IL-33, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and high serum immunoglobulin (Ig)G levels were assessed in 111 RA patients receiving a first course of 2 g RTX (cohort 1) in an observational study and in 74 RA patients treated with the same schedule in routine care (cohort 2). Univariate and multivariate analyses identified factors associated with a European League Against Rheumatism (EULAR) response at 24 weeks. At week 24, 84/111 (76%) and 54/74 (73%) patients reached EULAR response in cohorts 1 and 2, respectively. Serum IL-33 was detectable in only 33.5% of the patients. In the combined cohorts, the presence of RF or anti-CCP (odds ratio (OR) 3.27, 95% confidence interval (CI) 1.13-9.46; p = 0.03), high serum IgG (OR 2.32, 95% CI 1.01-5.33; p = 0.048), and detectable serum IL-33 (OR 2.40, 95% CI 1.01-5.72; p = 0.047) were all associated with RTX response in multivariate analysis. The combination of these three factors increased the likelihood of response to RTX. When serum IL-33 detection was added to seropositivity and serum IgG level, 100% of the patients with the three risk factors (corresponding to 9% of the population) responded to RTX (OR versus patients with none of the three risk factors 29.61, 95% CI 1.30-674.79; p = 0.034). Detectable serum IL-33 may predict clinical response to RTX independently of, and synergistically with, auto-antibodies and serum IgG level. NCT01126541 ; 18 May 2010.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 16%
Student > Postgraduate 8 13%
Researcher 8 13%
Student > Ph. D. Student 8 13%
Student > Bachelor 5 8%
Other 10 16%
Unknown 15 23%
Readers by discipline Count As %
Medicine and Dentistry 21 33%
Biochemistry, Genetics and Molecular Biology 6 9%
Agricultural and Biological Sciences 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Immunology and Microbiology 3 5%
Other 5 8%
Unknown 22 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 May 2017.
All research outputs
#1,192,428
of 19,789,905 outputs
Outputs from Arthritis Research & Therapy
#175
of 2,748 outputs
Outputs of similar age
#32,803
of 411,519 outputs
Outputs of similar age from Arthritis Research & Therapy
#16
of 219 outputs
Altmetric has tracked 19,789,905 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,748 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 411,519 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 219 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.